Despite a modest erosion to fundamentals and sector headwinds, Jefferies does not anticipate any dramatic earnings misses, which could help sentiment continue to turn around.
FDA rulings can make or break some companies. 24/7 Wall St. has collected eight key FDA decisions coming up in 2016 or 2017.
The top analyst upgrades, downgrades and initiations seen on Wednesday, March 23, include Charles Schwab, Dean Foods, HollyFrontier, Incyte, Newfield Exploration and Nike.
Despite the market rally, insiders are still buying at big levels, while insider selling remains dormant. This is a very positive sign for equity investors and the market as a whole.
These biotech companies 24/7 Wall St. has picked stood out from the rest with big moves over the course of last week.
Incyte reported better-than-expectged fourth-quarter financial results after the markets closed on Wednesday.
Chris Lange After the announcement that its Phase 2 trial of Ruxolitinib would be stopped a few analysts took a deeper look at Incyte and realized that it might not be as bad as…
Chris Lange Thursday's top analyst calls include Boeing, eBay, Facebook, Incyte, Kinder Morgan, PayPal, Qualcomm and U.S. Steel.
Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. It initiated several top biotech stocks with an Outperform rating.
Wednesday's top analyst calls include AMD, Amazon.com, Celgene, Comerica, Fortinet, Gilead Sciences, Lennar, Netflix, Voya and Wayfair.
The top analyst calls for Wednesday, January 6, 2016, include Bluebird Bio, Check Point Software, Comcast, Eli Lilly, Hyatt Hotels, Lockheed Martin and Rite Aid.
This week the Jefferies analysts are positive on companies that took a shot price-wise last week and may be offering an even better entry point for investors.
These three top biotech names are very good bets for investors looking to add high-quality companies with less volatility and binary clinical data risk.
These four top large cap biotechs are very good bets for investors looking to add high-quality companies with less volatility and binary clinical data risk.
In a new and very comprehensive report, Jefferies starts coverage on biotechs with some very targeted stock selections.
